Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
暂无分享,去创建一个
S. Sivertseva | G. Makshakov | M. Shumilina | E. Evdoshenko | E. Popova | N. Khachanova | M. Davydovskaya | D. Korobko | N. Neofidov | N. Malkova | I. Kalinin | E. Dubchenko | S. Shchur | A. Volkov | A. Stepanova | I. Vergunova | N. Pozhidaeva | A. Prilenskaya